home
enabling drug discovery in the ubiquitin field since 2010
Access to well-defined and advanced ubiquitin research tools and ubiquitin-like research tools is of paramount importance for drug development, fundamental research and structural studies. Since we founded our company in 2010, our ubiquitin and ubiquitin-like research tools have been well-recognised by both Pharma & Academia. Many leading laboratories in the field worldwide use our innovative and custom reagents. We also collaborate with outstanding scientists on research projects to further our insights in this growing field. We are proud that our joint efforts regularly result in publications in high-ranking journals. You can find examples in "our publications" section below this page. For an extensive list of our publications, please visit our resource download center.
Please explore how our ubiquitin research tools expedite the three stages of early drug discovery, i.e. target - lead - lead on target, by clicking on the buttons below:
target
Identify and validate your target using UbiQ Probes.
lead
Screen your compounds targeting DUBs and Ubl proteases using UbiQ Assay reagents.
lead on target
Our reagents enable you in lead on target validation and lead optimization.
target
Identify and validate your target using UbiQ Probes.
lead
Screen your compounds targeting DUBs and Ubl proteases using UbiQ Assay reagents.
lead on target
Our reagents enable you in lead on target validation and lead optimization.
catalogue ubiquitin reagents
In our laboratory at the Amsterdam Science Park, UbiQ develops, manufactures, and commercializes research tools such as ubiquitinated peptides, activity-based probes, and activity assay reagents. In addition to ubiquitin, we also make ubiquitin-like variants (SUMO, ISG15, NEDD8, etc.) of our reagents.
It is important to note that all our research tools are “For laboratory research use only, not for use in animals and humans".
custom ubiquitin reagents
With our UbiQ technologies we can synthesize in a site-selective manner ubiquitinated peptides and reagents that are not readily available through biological approaches. Next to our catalogue reagents, we offer a tailored chemical approach to producing specific ubiquitinated conjugates. This custom ubiquitin synthesis approach allows researchers to design unique ubiquitinated peptides and ubiquitin reagents.
our blog
Poster prize award at the GRK2243 Symposium Understanding Ubiquitylation
We congratulate Dr Cara Ellison from the University of Oxford with the Poster Prize award at the GRK2243 Symposium Understanding Ubiquitylation: From Molecular Mechanisms to Disease 2025, in Würzburg (Germany).
Live cell delivery of ubiquitin reagents by bead loading
We present a new protocol for intracellular delivery of our reagents (Figure 1). In protocol P010, (also in our resource download center), we outline a...
First Poster Prize award at the EMBO ubiquitin conference in Cavtat
We congratulate Dr Jason Collins from the National Institute of Dental and Craniofacial Research / NIH (Bethesda, USA) with the First Poster Prize award at the 2024 EMBO ubiquitin conference in Cavtat.
Poster Prize awardees at the Biochemical Society conference in Edinburgh
We congratulate the Poster Prize awardees at last week's Deubiquitylases and Ubl-proteases conference of the Biochemical Society in Edinburgh!
Launch of four new activity-based probes for deubiquitinating enzymes
We present four new HA-tagged activity-based probes for deubiquitinating enzymes (DUBs). UbiQ-216: HA-Ahx-Ahx-Ub-VAE (VAE= vinyl azido ester) UbiQ-217: HA-Ahx-Ahx-Ub-VAA (VAA= vinyl azido amide)
where to meet us
Lorne Ubiquitin – The Australian Ubiquitin Summit 2025
November 20 - 23, 2025 Lorne, Australia Lorne Ubiquitin - The Australia Ubiquitin Summit, 2025 Contact: Farid El Oualid (CSO, attending the conference) and Alfred Nijkerk (CEO, sponsorship)
Innovation For Health 2025
April 3, 2025 Rotterdam, the Netherlands Innovation For Health 2025 Contact: Alfred Nijkerk (CEO)
Symposium Understanding Ubiquitylation
June 2 - 4, 2025 Würzburg, Germany GRK2243 Symposium Understanding Ubiquitylation: From Molecular Mechanisms to Disease, 2025 Contact: Farid El Oualid (CSO) and Alfred Nijkerk (CEO) (sponsorship)
our publications
USP1/UAF1 targets polyubiquitinated PCNA with an exo-cleavage mechanism that can temporarily enrich for monoubiquitinated PCNA
UbiQ is proud to have contributed to this paper in Nature Communications (Nat Commun 2025, 16, 6991), describing our scientific adventures with USP1 and PCNA. If you are interested in DNA damage...
Characterization of the Ubiquitin and ISG15 Deconjugase Activity of SARS-CoV-1 and SARS-CoV-2 Papain-Like Protease
UbiQ is proud to have contributed a chapter to the Methods in Molecular Biology book series (MIMB,volume 2591), together with the Department of Biochemistry & Structural Biology,...
Catalytic and regulatory mechanisms of the dual-specificity ubiquitin/FAT10 E1 enzyme Uba6
UbiQ is proud to have been part of a major collaborative research project focused on studying the dual-specificity ubiquitin/FAT10 E1 enzyme Uba6 and whose results have been published in Nature Communications 2022,...
Collaborative research looks into the (essential) roles of ubiquitin proteases (DUBs) and ubiquitin conjugation in Leishmania parasites
21st Royal Society of Chemistry - Medicinal Chemistry Symposium, 13 - 15 September 2021, Cambridge UK. Poster title: A ubiquitin activating enzyme as a novel therapeutic target for leishmaniasis. Daniel Harris (1), Dr Mads Gabrielson (2), Dr...
Anti–COVID-19 Drug Design by targeting a molecular scissor of Ubiquitin and ISG15
UbiQ is proud to have been part of a major collaboration reported recently by Rut et al. in Science Advances (2020, 6, eabd4596) describing the activity profiling and crystal structures of inhibitor...
Discover the many possibilities with our tools
UbiQ remains committed to advancing the ubiquitin research landscape through our state-of-the-art reagents and innovative chemical approaches. Our dedication to collaboration and research excellence ensures we remain at the forefront of this dynamic field. Reach out to us by filling out our contact form.